{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T04:26:52Z","timestamp":1768192012259,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,17]],"date-time":"2006-01-17T00:00:00Z","timestamp":1137456000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>After development of hormone-refractory metastatic disease, prostate cancer is incurable. The recent history of chemotherapy has shown that with difficult disease targets, combinatorial therapy frequently offers the best chance of a cure. In this study we have examined the effects of a combination of zoledronic acid (ZOL), a new-generation bisphosphonate, and docetaxel on LuCaP 23.1, a prostate cancer xenograft that stimulates the osteoblastic reaction when grown in the bone environment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Intra-tibial injections of LuCaP 23.1 cells were used to generate tumors in the bone environment, and animals were treated with ZOL, docetaxel, or a combination of these. Effects on bone and tumor were evaluated by measurements of bone mineral density and histomorphometrical analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>ZOL decreased proliferation of LuCaP 23.1 in the bone environment, while docetaxel at a dose that effectively inhibited growth of subcutaneous tumors did not show any effects in the bone environment. The combination of the drugs significantly inhibited the growth of LuCaP 23.1 tumors in the bone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In conclusion, the use of the osteolysis-inhibitory agent ZOL in combination with docetaxel inhibits growth of prostate tumors in bone and represents a potential treatment option.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-6-15","type":"journal-article","created":{"date-parts":[[2006,1,23]],"date-time":"2006-01-23T12:43:57Z","timestamp":1138020237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment"],"prefix":"10.1186","volume":"6","author":[{"given":"Kristen D","family":"Brubaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisha G","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Vessella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,17]]},"reference":[{"key":"367_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3322\/canjclin.52.3.154","volume":"52","author":"BA Hellerstedt","year":"2002","unstructured":"Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002, 52: 154-179.","journal-title":"CA Cancer J Clin"},{"key":"367_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0093-7754(01)90259-3","volume":"28","author":"JR Green","year":"2001","unstructured":"Green JR: Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol. 2001, 28: 4-10. 10.1016\/S0093-7754(01)90259-3.","journal-title":"Semin Oncol"},{"key":"367_CR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001, 19: 558-567.","journal-title":"J Clin Oncol"},{"key":"367_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/BF02555852","volume":"49","author":"AM Flanagan","year":"1991","unstructured":"Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991, 49: 407-415.","journal-title":"Calcif Tissue Int"},{"key":"367_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0093-7754(01)90264-7","volume":"28","author":"H Fleisch","year":"2001","unstructured":"Fleisch H: Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease. Semin Oncol. 2001, 28: 45-47. 10.1016\/S0093-7754(01)90264-7.","journal-title":"Semin Oncol"},{"key":"367_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/bmj.297.6651.772","volume":"297","author":"AR Morton","year":"1988","unstructured":"Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988, 297: 772-773.","journal-title":"BMJ"},{"key":"367_CR7","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995, 10: 1478-1487.","journal-title":"J Bone Miner Res"},{"key":"367_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","volume":"98","author":"CM Shipman","year":"1997","unstructured":"Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997, 98: 665-672. 10.1046\/j.1365-2141.1997.2713086.x.","journal-title":"Br J Haematol"},{"key":"367_CR9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.","journal-title":"Br J Cancer"},{"key":"367_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","volume":"84","author":"PS Mackie","year":"2001","unstructured":"Mackie PS, Fisher JL, Zhou H, Choong PF: Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001, 84: 951-958. 10.1054\/bjoc.2000.1679.","journal-title":"Br J Cancer"},{"key":"367_CR11","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1359\/jbmr.2001.16.11.2027","volume":"16","author":"O Peyruchaud","year":"2001","unstructured":"Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001, 16: 2027-2034.","journal-title":"J Bone Miner Res"},{"key":"367_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","volume":"28","author":"GR Mundy","year":"2001","unstructured":"Mundy GR, Yoneda T, Hiraga T: Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol. 2001, 28: 35-44. 10.1016\/S0093-7754(01)90263-5.","journal-title":"Semin Oncol"},{"key":"367_CR13","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001, 61: 2602-2608.","journal-title":"Cancer Res"},{"key":"367_CR14","first-page":"5564","volume":"62","author":"YP Lee","year":"2002","unstructured":"Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR: Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002, 62: 5564-5570.","journal-title":"Cancer Res"},{"key":"367_CR15","first-page":"295","volume":"9","author":"E Corey","year":"2003","unstructured":"Corey E, Brown LG, Quinn JE, Poot M, M.P R, Higano CS, R.L. V: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003, 9: 295-306.","journal-title":"Clin Cancer Res"},{"key":"367_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/pros.10363","volume":"59","author":"R Tenta","year":"2004","unstructured":"Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M: Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate. 2004, 59: 120-131. 10.1002\/pros.10363.","journal-title":"Prostate"},{"key":"367_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1464-4096.2004.04831.x","volume":"94","author":"JP Coxon","year":"2004","unstructured":"Coxon JP, Oades GM, Kirby RS, Colston KW: Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004, 94: 164-170. 10.1111\/j.1464-4096.2004.04831.x.","journal-title":"BJU Int"},{"key":"367_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","volume":"46","author":"R Montague","year":"2004","unstructured":"Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW: Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol. 2004, 46: 389-401. 10.1016\/j.eururo.2004.04.022.","journal-title":"Eur Urol"},{"key":"367_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.pcan.4500815","volume":"8","author":"JE Quinn","year":"2005","unstructured":"Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E: Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 2005, 8: 253-259. 10.1038\/sj.pcan.4500815.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"367_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","volume":"10","author":"JR Berenson","year":"2005","unstructured":"Berenson JR: Recommendations for zoledronic Acid treatment of patients with bone metastases. Oncologist. 2005, 10: 52-62. 10.1634\/theoncologist.10-1-52.","journal-title":"Oncologist"},{"key":"367_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","volume":"9","author":"CL Vogel","year":"2004","unstructured":"Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA: Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004, 9: 687-695. 10.1634\/theoncologist.9-6-687.","journal-title":"Oncologist"},{"key":"367_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1540-0352(11)70065-8","volume":"3","author":"N Price","year":"2004","unstructured":"Price N: Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer. Clin Prostate Cancer. 2004, 3: 77-79.","journal-title":"Clin Prostate Cancer"},{"key":"367_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/jnci\/djh294","volume":"96","author":"CC Parker","year":"2004","unstructured":"Parker CC: Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004, 96: 1480-1481.","journal-title":"J Natl Cancer Inst"},{"key":"367_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/cncr.20459","volume":"101","author":"K Altundag","year":"2004","unstructured":"Altundag K, Altundag O, Morandi P, Gunduz M: High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004, 101: 1101-1102. 10.1002\/cncr.20459.","journal-title":"Cancer"},{"key":"367_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1464-4096.2004.04919.x","volume":"94","author":"D Vordos","year":"2004","unstructured":"Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, de la TA: Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2004, 94: 524-527. 10.1111\/j.1464-4096.2004.04919.x.","journal-title":"BJU Int"},{"key":"367_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","volume":"31","author":"CS Higano","year":"2004","unstructured":"Higano CS: Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004, 31: 331-352. 10.1016\/j.ucl.2004.01.001.","journal-title":"Urol Clin North Am"},{"key":"367_CR27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jnci\/djh234","volume":"96","author":"E Winquist","year":"2004","unstructured":"Winquist E, Berry S: Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2004, 96: 1183-1184.","journal-title":"J Natl Cancer Inst"},{"key":"367_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","volume":"4","author":"F Saad","year":"2005","unstructured":"Saad F: Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer. 2005, 4: 31-37.","journal-title":"Clin Prostate Cancer"},{"key":"367_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1464-410X.2005.05441.x","volume":"95","author":"CC Parker","year":"2005","unstructured":"Parker CC: The role of bisphosphonates in the treatment of prostate cancer. BJU Int. 2005, 95: 935-938. 10.1111\/j.1464-410X.2005.05441.x.","journal-title":"BJU Int"},{"key":"367_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/02841860510029644","volume":"44","author":"JR Green","year":"2005","unstructured":"Green JR: Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol. 2005, 44: 282-292.","journal-title":"Acta Oncol"},{"key":"367_CR31","first-page":"1","volume-title":"Cancer Chemother Pharmacol","author":"G Bertelli","year":"2005","unstructured":"Bertelli G, Heouaine A, Arena G, Botto A, Garrone O, Colantonio I, Occelli M, Fea E, Giubergia S, Merlano M: Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol. 2005, 1-6."},{"key":"367_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000078328","volume":"66","author":"JM Ferrero","year":"2004","unstructured":"Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, Lesbats G, Garnier G, Boublil JL, Tchiknavorian X, Chevallier D, Amiel J: A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology. 2004, 66: 281-287. 10.1159\/000078328.","journal-title":"Oncology"},{"key":"367_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.urology.2004.08.041","volume":"65","author":"E Efstathiou","year":"2005","unstructured":"Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A: Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology. 2005, 65: 126-130. 10.1016\/j.urology.2004.08.041.","journal-title":"Urology"},{"key":"367_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/cncr.11082","volume":"97","author":"AD Tiersten","year":"2003","unstructured":"Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP: A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003, 97: 537-544. 10.1002\/cncr.11082.","journal-title":"Cancer"},{"key":"367_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/A:1023756707900","volume":"63","author":"S Oudard","year":"2003","unstructured":"Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, Delattre JY: Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2003, 63: 81-86. 10.1023\/A:1023756707900.","journal-title":"J Neurooncol"},{"key":"367_CR36","first-page":"38","volume":"12 Suppl 2","author":"CS Higano","year":"2005","unstructured":"Higano CS: Current status of treatment for patients with metastatic prostate cancer. Can J Urol. 2005, 12 Suppl 2: 38-41.","journal-title":"Can J Urol"},{"key":"367_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","volume":"83","author":"S Magnetto","year":"1999","unstructured":"Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999, 83: 263-269. 10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T.","journal-title":"Int J Cancer"},{"key":"367_CR38","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami H, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84: 1126-1134. 10.1054\/bjoc.2001.1727.","journal-title":"Br J Cancer"},{"key":"367_CR39","first-page":"116","volume":"16","author":"ME Stearns","year":"1996","unstructured":"Stearns ME, Wang M: Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996, 16: 116-131.","journal-title":"Invasion Metastasis"},{"key":"367_CR40","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996, 335: 1785-1791. 10.1056\/NEJM199612123352401.","journal-title":"N Engl J Med"},{"key":"367_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056\/NEJM199808063390601.","journal-title":"N Engl J Med"},{"key":"367_CR42","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A: Bisphosphonates and breast carcinoma: present and future. Cancer. 2000, 88: 3033-3037. 10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C.","journal-title":"Cancer"},{"key":"367_CR43","first-page":"1039","volume":"2","author":"WJ Ellis","year":"1996","unstructured":"Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH: Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res. 1996, 2: 1039-1048.","journal-title":"Clin Cancer Res"},{"key":"367_CR44","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.urology.2003.12.022","volume":"63","author":"NM Tiffany","year":"2004","unstructured":"Tiffany NM, Wersinger EM, Garzotto M, Beer TM: Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology. 2004, 63: 934-939. 10.1016\/j.urology.2003.12.022.","journal-title":"Urology"},{"key":"367_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","volume":"1","author":"F Saad","year":"2002","unstructured":"Saad F: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer. 2002, 1: 145-152.","journal-title":"Clin Prostate Cancer"},{"key":"367_CR46","first-page":"2897","volume":"24","author":"K Fizazi","year":"2004","unstructured":"Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM: High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004, 24: 2897-2903.","journal-title":"Anticancer Res"},{"key":"367_CR47","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","volume":"65","author":"SJ Kim","year":"2005","unstructured":"Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ: Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res. 2005, 65: 3707-3715. 10.1158\/0008-5472.CAN-04-3601.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-6-15\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:34:49Z","timestamp":1630449289000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-6-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,17]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-6-15","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,17]]},"assertion":[{"value":"2 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"15"}}